Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $261.7 million.

  • Summit Therapeutics' Liabilities and Shareholders Equity fell 4795.11% to $261.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1475.86%. This contributed to the annual value of $435.6 million for FY2024, which is 11461.55% up from last year.
  • Summit Therapeutics' Liabilities and Shareholders Equity amounted to $261.7 million in Q3 2025, which was down 4795.11% from $324.0 million recorded in Q2 2025.
  • Summit Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $664.2 million during Q4 2022, with a 5-year trough of $95.7 million in Q2 2022.
  • For the 5-year period, Summit Therapeutics' Liabilities and Shareholders Equity averaged around $257.9 million, with its median value being $218.5 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 48582.04% in 2022, then crashed by 6944.31% in 2023.
  • Over the past 5 years, Summit Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $113.4 million in 2021, then soared by 485.82% to $664.2 million in 2022, then crashed by 69.44% to $202.9 million in 2023, then soared by 114.62% to $435.6 million in 2024, then plummeted by 39.91% to $261.7 million in 2025.
  • Its last three reported values are $261.7 million in Q3 2025, $324.0 million for Q2 2025, and $383.8 million during Q1 2025.